UK firm to trial T-cell Covid vaccine that could give longer immunity

Exclusive: Oxfordshire-based Emergex gets go-ahead for trials in Switzerland for skin patch vaccine

• Coronavirus – latest updates
• See all our coronavirus coverage

An Oxfordshire-based company will soon start clinical trials of a second-generation vaccine against Covid-19, an easy-to-administer skin patch that uses T-cells to kill infected cells and could offer longer-lasting immunity than current vaccines.

Emergex was set up in Abingdon in 2016 to develop T-cell vaccines, the brainchild of Prof Thomas Rademacher, the firm’s chief executive and professor emeritus of molecular medicine at the University College London medical school.

Continue reading...

from The Guardian https://ift.tt/30m6Zwf
via IFTTT